FDA Approves First Interchangeable Biosimilar Insulin Product …
Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes.
FDA Approves Insulin Glargine-yfgn as First Interchangeable Biosimilar …
2021年7月29日 · Officials with the FDA have approved the first interchangeable biosimilar insulin product for patients with type 1 or type 2 diabetes mellitus. Insulin glargine-yfgn (Semglee) is biosimilar to and interchangeable with insulin glargine (Lantus), a long-acting insulin analog.
SEMGLEE - (insulin glargine-yfgn) injection Homepage
What is SEMGLEE (insulin glargine-yfgn) injection 100 Units/mL? SEMGLEE is a prescription long-acting man-made insulin used to control high blood sugar in adults and children with diabetes. SEMGLEE is not for use to treat diabetic ketoacidosis.
Introduction to Two Recently Approved Insulin Glargine Biosimilars
2022年6月16日 · Two insulin biosimilars for insulin glargine (Lantus), a subcutaneous long-acting insulin analogue for improving glycemic control, have recently been approved: Semglee (insulin glargine-ygfn), which is an interchangeable product, and Rezvoglar (insulin glargine-aglr), which is not interchangeable.
Biocon’s Insulin Glargine - Insulin Glargine
2021年7月28日 · Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes. Approval of these insulin products can provide patients with additional safe, high-quality and potentially cost …
Common Patient Questions About Insulin Biosimilars Pertain to ...
2023年9月18日 · Insulin glargine (Basaglar; Eli Lilly) was approved by the FDA as a “follow-on” product. These are approved under the Federal Food, Drug, and Cosmetic Act 505(b)(2) under an abbreviated pathway and considered to be similar to the previously approved reference drug.
Semglee (insulin glargine-yfgn) Uses, Dosage, Side Effects - Drugs.com
Semglee (insulin glargine-yfgn) is used for type 1 and type 2 diabetes mellitus. Includes Semglee side effects, interactions and indications.
The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn
Many patients who could not previously afford insulin therapy may now have significantly improved access to treatment. Providers will need education to increase awareness of these new biosimilars and interchangeable biosimilar insulin products, …
First Interchangeable Biosimilar to Insulin Found Noninferior Insulin …
2023年9月19日 · Insulin glargine-yfgn 100 units/mL (Semglee; Biocon Biologics) is the first FDA-approved interchangeable biosimilar to insulin glargine (reference biologic) that patients with type 1 and type 2 diabetes (T1D and T2D, respectively) can access without prescriber consultation.
Semglee vs Lantus: How Do These Insulins Compare? - GoodRx
2024年2月23日 · Semglee (insulin glargine-yfgn) was approved in July 2021 as the first interchangeable biosimilar to Lantus. You can expect similar clinical benefits, side effects, and risks with both insulins. Factors such as cost and insurance coverage may help determine which is …